image
Mobile_image
headline

Treatment considerations for DLBCL

eyebrow
For adults with relapsed or refractory DLBCL
collection-container
content-container
collection-container-variant
grid
collection-item-type
core-content, core-text
icon
headline

Considerations when making a treatment decision

content

Here are some important considerations that can help you feel confident about your treatment choice:

  • How treatments work to kill cancer cells
  • How well treatments may stop or slow the progress of your cancer
  • How well treatments may improve overall survival
  • How well results may be maintained long-term
  • How side effects compare among treatments, and how they may be managed
  • Dosing and how treatments are given
  • The type of patient support available during treatment
icon
headline

Our Treatment Decision Guide can help

content

This downloadable guide helps answer these and other questions many relapsed or refractory DLBCL patients have.

Use the guide to review the effectiveness of ADCETRIS plus lenolidomide and rituximab for patients with DLBCL that has come back (relapsed) or didn’t respond (refractory) after 2 or more prior treatments and who are not candidates for stem cell transplant (HSCT) or CAR-T therapy.

buttons
Download the guide
headline

Being informed matters with relapsed or refractory DLBCL

image
Mobile_image
headline

Did you know?

content

Between 30% and 40% of people with DLBCL will experience a relapse or have a refractory response after initial treatment.

ADCETRIS plus lenalidomide and rituximab is an option for these patients after 2 or more prior treatments and if they are not candidates for a stem cell transplant or CAR-T cell therapy.

collection-container
content-container
collection-container-variant
grid, 2-column
collection-item-type
core-content, core-text
Headline

Your treatment, your choice.

content
Your voice matters when it comes to making a treatment decision for relapsed or refractory DLBCL. While your doctor is the expert regarding your diagnosis, you and your care team are equal partners in the treatment decision. Your perspective and concerns play an essential role in selecting a treatment that works for you. To take an active part in your care:
icon
headline
content
Don’t hesitate to speak up and ask questions
icon
headline
content
It’s OK to propose an option your doctor may not mention
icon
headline
content
Familiarize yourself with all available treatments
icon
headline
content
Seek a second opinion if that will help you feel confident about your choice
headline

If you’re considering a treatment for relapsed or refractory DLBCL, ADCETRIS plus lenalidomide and rituximab may be an option for you

content
The ECHELON-3 study evaluated the efficacy and safety of ADCETRIS in adults with diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or didn’t respond (refractory) to 2 or more prior treatments and who are not candidates for stem cell transplant (HSCT) or CAR-T therapy.
buttons
See study results
headline

Glossary

content

CAR-T cell therapy: A cancer treatment in which a type of immune system cell from the patient’s blood is changed in the laboratory so they will attack cancer cells.

Refractory: When cancer does not respond or stopped responding to treatment.

Relapse: When cancer has returned after signs and symptoms of cancer had reduced or became undetectable.

Stem cell transplant: A procedure in which a patient receives healthy stem cells (blood-forming cells) to replace their own stem cells that have been destroyed by certain cancer treatments.